Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

Virological failure and subsequent resistance profiles in individuals exposed to atazanavir.

Stebbing J, Nathan B, Jones R, McKenna A, Powles T, Bower M, Holmes P, Gazzard B, Nelson M.

AIDS. 2007 Aug 20;21(13):1826-8.

PMID:
17690587
2.

Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy.

Karlström O, Josephson F, Sönnerborg A.

J Acquir Immune Defic Syndr. 2007 Apr 1;44(4):417-22.

PMID:
17159658
3.

Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients.

Vora S, Marcelin AG, Günthard HF, Flandre P, Hirsch HH, Masquelier B, Zinkernagel A, Peytavin G, Calvez V, Perrin L, Yerly S; Swiss HIV Cohort Study.

AIDS. 2006 Jan 2;20(1):35-40.

PMID:
16327317
4.

Atazanavir/ritonavir: a review of its use in HIV therapy.

von Hentig N.

Drugs Today (Barc). 2008 Feb;44(2):103-32. doi: 10.1358/dot.2008.44.2.1137107. Review.

PMID:
18389089
5.

Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients.

Santoro MM, Bertoli A, Lorenzini P, Ceccherini-Silberstein F, Gianotti N, Mussini C, Torti C, Di Perri G, Barbarini G, Bini T, Melzi S, Caramello P, Maserati R, Narciso P, Micheli V, Antinori A, Perno CF; CARe Study Group.

Infection. 2009 Jun;37(3):233-43. doi: 10.1007/s15010-008-8065-4. Epub 2009 Jan 23.

PMID:
19169632
6.

External validation of atazanavir/ritonavir genotypic score in HIV-1 protease inhibitor-experienced patients.

Marcelin AG, Chazallon C, Gérard L, Saïdi Y, Aboulker JP, Girard PM, Calvez V, Piketty C.

J Acquir Immune Defic Syndr. 2006 May;42(1):127-8. No abstract available.

PMID:
16639354
7.

Impact of first-line protease inhibitors on predicted resistance to tipranavir in HIV-1-infected patients with virological failure.

Hsieh SM, Chang SY, Hung CC, Sheng WH, Chen MY, Chang SC.

BMC Infect Dis. 2009 Sep 14;9:154. doi: 10.1186/1471-2334-9-154.

8.

Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.

Landman R, Capitant C, Descamps D, Chazallon C, Peytavin G, Katlama C, Pialoux G, Bentata M, Brun-Vézinet F, Aboulker JP, Yéni P; ANRS 127 Study Group.

J Antimicrob Chemother. 2009 Jul;64(1):118-25. doi: 10.1093/jac/dkp146. Epub 2009 May 6.

9.

Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.

Soriano V, García-Gasco P, Vispo E, Ruiz-Sancho A, Blanco F, Martín-Carbonero L, Rodríguez-Novoa S, Morello J, de Mendoza C, Rivas P, Barreiro P, González-Lahoz J.

J Antimicrob Chemother. 2008 Jan;61(1):200-5. Epub 2007 Nov 13.

11.

Atazanavir: improving the HIV protease inhibitor class.

Becker S.

Expert Rev Anti Infect Ther. 2003 Oct;1(3):403-13. Review.

PMID:
15482137
12.

Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.

Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, Lichtenstein K, Rightmire A, Sankoh S, Wilber R.

AIDS. 2005 Jan 28;19(2):153-62. No abstract available. Corrected and republished in: AIDS. 2005 Apr 29;19(7):685-94.

PMID:
15668540
13.

Atazanavir: a new protease inhibitor to treat HIV infection.

Musial BL, Chojnacki JK, Coleman CI.

Am J Health Syst Pharm. 2004 Jul 1;61(13):1365-74. Review. Erratum in: Am J Health Syst Pharm. 2004 Nov 1;61(21):2243.

PMID:
15287232
14.

HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review.

Bierman WF, van Agtmael MA, Nijhuis M, Danner SA, Boucher CA.

AIDS. 2009 Jan 28;23(3):279-91. doi: 10.1097/QAD.0b013e32831c54e5. Review.

PMID:
19114854
15.

[Efficacy of atazanavir in simplification regimens].

Zamora L, Gatell JM.

Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 17:14-21. doi: 10.1016/S0213-005X(08)76615-1. Review. Spanish.

PMID:
20116612
16.

Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir.

Manosuthi W, Sungkanuparph S, Ruxrungtham K, Prasithsirikul W, Athichathanabadi C, Tantisiriwat W, Bowonwatanuwong C, Chumpathat N, Chaovavanich A.

J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):127-9. No abstract available.

PMID:
18156994
17.

[Viral resistance and genetic barrier of atazanavir].

Mendoza CD, Garrido C, Treviño A, Anta L, Poveda E, Soriano V.

Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 17:28-33. doi: 10.1016/S0213-005X(08)76617-5. Spanish.

PMID:
20116614
18.

Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.

Cleijsen RM, van de Ende ME, Kroon FP, Lunel FV, Koopmans PP, Gras L, de Wolf F, Burger DM.

J Antimicrob Chemother. 2007 Oct;60(4):897-900. Epub 2007 Aug 17.

19.

[Atazanavir protects lipid metabolism. New PI with favorable metabolic profile].

[No authors listed]

MMW Fortschr Med. 2004 Apr 26;146 Spec No 1:90. German. No abstract available.

PMID:
15373065
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk